Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by...
  • termaxima@slrpnk.netEnglish
    5·
    12 days ago

    And enjoy the 5 cancers you just caused yourself by editing other genes that happen to contain the targeted sequence !